Equity Overview
Price & Market Data
Price: $1.57
Daily Change: -$0.05 / 3.18%
Range: $1.55 - $1.60
Market Cap: $3,567,687
Volume: 12,964
Performance Metrics
1 Week: 14.49%
1 Month: -9.20%
3 Months: -46.09%
6 Months: -67.15%
1 Year: -63.57%
YTD: -50.47%
Company Details
Employees: 6
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Israel
Details
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.